Treatment of an inherited disorder of cholesterol metabolism by pathogenesis-based therapy

Treatment of an inherited disorder of cholesterol metabolism by pathogenesis-based therapy - Treatment of an inherited disorder of cholesterol metabolism by pathogenesis-based therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024307

Enrollment

Registered

2016-11-01

Start date

2017-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

an inherited disorder of cholesterol metabolism

Interventions

Topical application of 1% atorvastatin or control (paraben water) (24 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with an inherited disorder of cholesterol metabolism, confirmed by genetic diagnosis or sterol profile analysis of skin

Exclusion criteria

Exclusion criteria: Past histroy of allergic reaction for atorvastatin Severe hepatic disease/disorder (AST or ALT > normal limits*1.25) During administration of Telaprevir Women who are or may be pregnant Participants in other clinical trials or researchs at the registration Patients who are judged inappropriate for the trial by lead principal investigator or other participating doctors

Design outcomes

Primary

Measure	Time frame
Improvement of skin condition after 24 weeks of treatment	—

Secondary

Measure	Time frame
Evaluation of intermediate of cholesterol in the patients' skin Skin biopsy	—

Countries

Japan

Contacts

Public ContactAtsuo Kikuchi

Tohoku University Hospital Department of Pediatrics

akikuchi-thk@umin.ac.jp022-717-7287

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026